SREEVANI KUNCHAM: Open Payments
NPI 1528030210 · LEWISVILLE, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$668 in 32 payments from 13 companies in 2025. Trend: 2023 $682 · 2024 $802 · 2025 $668
Food & beverage: $598Education: $70
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 4 | $96 |
| Novo Nordisk Inc | 4 | $87 |
| AstraZeneca Pharmaceuticals LP | 5 | $87 |
| Astellas Pharma US Inc | 2 | $84 |
| Otsuka America Pharmaceutical, Inc. | 5 | $83 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $61 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $44 |
| Lilly USA, LLC | 2 | $44 |
| Amgen Inc. | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
Products named: REXULTI, Ozempic, JARDIANCE, SHINGRIX, AIRSUPRA, CAPLYTA, MOUNJARO, KISUNLA.
Industry payments across TX — which companies pay providers there.
